RXi Pharmaceuticals Looks Beyond RNAi Therapeutics with Apthera Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 4 (Table of Contents)
Published: 21 Apr-2011
DOI: 10.3833/pdr.v2011.i4.1461 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
RXi Pharmaceuticals, a developer of RNAi therapeutics, has decided to expand its focus beyond gene silencing by acquiring the privately held cancer immunotherapy company Apthera and its promising clinical-stage cancer vaccine, NeuVax™...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS